Group 1 - The company held its second board meeting of the seventh session on August 18, 2025, with all nine directors present, and the meeting was deemed legally valid [2][3]. - The board approved a proposal to reduce the total amount of funds raised through a simplified procedure for issuing shares to specific targets from 175.29 million yuan to 125.29 million yuan [3][7]. - The number of shares to be issued was adjusted from 12,785,769 shares to 9,138,795 shares, which does not exceed 30% of the company's total share capital before the issuance [4][6]. Group 2 - The adjusted total amount of funds to be raised is 125.29 million yuan, which is still within the limit of 300 million yuan and does not exceed 20% of the company's net assets at the end of the previous year [7][26]. - The net proceeds from the fundraising will be invested in projects related to vaccine research and production, with the company allowed to adjust the investment sequence and amounts based on actual needs [6][34]. - The board also approved a feasibility analysis report regarding the use of funds raised through the issuance of shares, confirming that the funds will be used for projects in the field of technological innovation [12][18]. Group 3 - The company has committed to measures to mitigate the dilution of immediate returns resulting from the share issuance, including maintaining stable business growth and accelerating project investment [40][46]. - The company has a strong talent reserve, with a stable management team and ongoing recruitment efforts to enhance its human resources [36]. - The company has established a comprehensive technical reserve, focusing on vaccine research and development, and has formed partnerships with academic institutions to enhance its innovation capabilities [37][38]. Group 4 - The company plans to strengthen its fundraising management to ensure compliance and effective use of the raised funds, with regular checks and disclosures on fund usage [42]. - The company aims to accelerate the construction of fundraising investment projects to enhance its competitiveness and sustainable development [43]. - The company has developed a profit distribution policy to ensure stable returns for investors, particularly small and medium shareholders [44][45].

证券代码：688319 证券简称：欧林生物 公告编号：2025-035 成都欧林生物科技股份有限公司 第七届董事会第二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 成都欧林生物科技股份有限公司（以下简称"公司"）于 2025 年 8 月 18 日以现场及通讯方式在公司会议室召开第七届董事会第二次会议（以下简称"本 次会议"）。经全体董事同意，本次会议豁免通知时限要求。本次会议由公司董 事长樊绍文先生召集并主持，应出席董事 9 人，实际出席会议董事 9 人。本次会 议的通知、召开及审议程序符合《中华人民共和国公司法》《上海证券交易所科 创板股票上市规则》等法律法规、规范性文件及《成都欧林生物科技股份有限公 司章程》（以下简称"《公司章程》"）的有关规定，会议决议合法有效。 二、董事会会议审议情况 经与会董事审议，本次会议通过如下议案： （一）审议通过了《关于调减公司以简易程序向特定对象发行股票募集资 金总额暨调整发行方案的议案》 根据《中华人民共和国证券法》《上市公司证券发行注册管理 ...

成都欧林生物科技股份有限公司第七届董事会 独立董事专门会议 2025 年第一次会议决议 一、独立董事专门会议召开情况 成都欧林生物科技股份有限公司（以下简称"公司"）第七届董事会独立董 事专门会议 2025 年第一次会议于 2025 年 8 月 18 日在公司会议室以现场及通讯 方式召开。本次会议由独立董事陈正旭先生主持，应出席独立董事 3 名，实际出 席独立董事 3 名。本次会议的召集和召开程序符合《上市公司独立董事管理办法》 《上海证券交易所科创板股票上市规则》的相关规定，会议决议合法有效。 二、独立董事专门会议审议情况 本着勤勉尽责、客观公正的原则，经与会独立董事审议，以投票表决方式通 过以下议案： （一）审议通过了《关于调减公司以简易程序向特定对象发行股票募集资 金总额暨调整发行方案的议案》 经审阅，我们认为：公司编制的《成都欧林生物科技股份有限公司以简易程 序向特定对象发行人民币普通股（A 股）股票募集资金使用可行性分析报告（二 次修订稿）》符合《中华人民共和国公司法》《中华人民共和国证券法》及《上 市公司证券发行注册管理办法》等法律法规、规范性文件的有关规定，符合本次 发行的竞价结果及公司具体情况 ...

Core Viewpoint - Chengdu Olin Biological Technology Co., Ltd. plans to issue A-shares to specific investors, which may dilute immediate returns, and has proposed measures to compensate for this dilution [1][5]. Financial Impact of the Issuance - The issuance is expected to impact key financial metrics, with three scenarios analyzed for the net profit attributable to shareholders in 2025 compared to 2024: a 10% increase, no change, and a 10% decrease [2][3][4]. - In the first scenario, the net profit would rise to CNY 22.83 million, with basic and diluted earnings per share (EPS) at CNY 0.0559 [3]. - In the second scenario, the net profit remains at CNY 20.76 million, with basic and diluted EPS at CNY 0.0508 [4]. - In the third scenario, the net profit would drop to CNY 18.68 million, with basic and diluted EPS at CNY 0.0458 [4]. Necessity and Reasonableness of the Issuance - The funds raised will be used for a vaccine R&D production base technology renovation project, which aligns with the company's core business and development strategy [5][6]. - The project aims to enhance production capabilities and ensure stable revenue generation, supporting long-term R&D and market promotion [5][6]. Company’s Preparedness in Talent, Technology, and Market - The company has a stable management team with extensive experience in the biopharmaceutical industry, ensuring ongoing support for sustainable development [6][7]. - The R&D team has over ten years of experience in vaccine development, focusing on both traditional and innovative vaccine projects [7][8]. - The company has established multiple vaccine R&D platforms and holds several patents, enhancing its competitive edge in the market [8]. Measures to Mitigate Dilution of Immediate Returns - The company commits to maintaining stable and rapid growth in its core business and accelerating the investment progress of the fundraising projects to enhance profitability [9][12]. - It will manage the raised funds strictly according to legal regulations to ensure compliance and effective use [11][12]. - The company plans to improve its profit distribution policy to ensure reasonable returns for investors, particularly small shareholders [12][13]. Commitments from Major Stakeholders - The controlling shareholder and actual controller have made commitments to uphold the company's independence and ensure the fulfillment of compensation measures for diluted returns [14][15]. - The board of directors and senior management have also pledged to avoid actions that could harm the company's interests and to adhere to the commitments made regarding return compensation [15][17].

Fundraising Plan - The company plans to raise a total of up to RMB 300 million, with a net amount of RMB 125.29 million allocated for specific projects after deducting related issuance costs [1] - The total investment for the projects is RMB 290 million, which aligns with national industrial policies and does not involve overcapacity or high-energy-consuming industries [1] Project Overview - The fundraising project focuses on the "Vaccine R&D Production Base Technical Renovation Project," which includes upgrading production lines for major products such as tetanus and polysaccharide vaccines [2] - The project aims to replace old production lines with new automated and intelligent production lines while maintaining overall production capacity stability [2][3] Necessity of the Project - The project is necessary to adapt to industry trends and improve production management, ensuring compliance with vaccine production quality management standards [2][3] - The renovation will enhance production efficiency and product quality, which is crucial for the company's main revenue sources [3] Competitive Advantage - The vaccine industry is technology-intensive, requiring continuous innovation and improvement to maintain competitiveness [4] - The project will support the stable production of core products, providing cash flow for ongoing research and development of new products [4] Feasibility of the Project - The project aligns with national policies promoting equipment upgrades in the pharmaceutical industry, enhancing production quality and efficiency [5] - The company has established a robust quality management system that complies with various regulations, ensuring product quality throughout the production lifecycle [6] Implementation and Economic Impact - The project will be implemented over four years, with funding allocated based on project progress [8] - The project is expected to enhance the company's production capabilities and financial health, leading to improved long-term profitability and reduced financial risks [12] Conclusion - The fundraising project is in line with national policies and industry trends, aiming to optimize production processes and enhance product quality, thereby ensuring the company's competitive advantage and sustainable growth [12][13]

Core Viewpoint - The fundraising project by Chengdu Olin Biotechnology Co., Ltd. focuses on technological innovation in the vaccine industry, aiming to enhance production efficiency and product quality through the upgrade of existing production lines [12][14][15]. Group 1: Company Overview - Chengdu Olin Biotechnology Co., Ltd. specializes in the research, production, and sales of human vaccines, having developed a product pipeline that includes marketed products such as adsorbed tetanus vaccine, Hib conjugate vaccine, and AC conjugate vaccine [1][13]. - The company has a strong R&D capability with multiple vaccine development platforms and has accumulated several patents in the field of human vaccine research and industrialization [9][13]. Group 2: Fundraising and Investment Plan - The total amount to be raised from the current issuance is capped at 300 million RMB, with a net amount of approximately 125.29 million RMB allocated for specific projects [2][12]. - The main investment project is the "Vaccine R&D Production Base Technology Renovation Project," which involves upgrading production facilities to improve production efficiency and product quality [3][4]. Group 3: Project Details and Necessity - The project will replace old production lines with new automated and intelligent production lines, ensuring stable overall production capacity while enhancing production conditions for key products [3][4][5]. - The necessity of the project is underscored by the need to comply with vaccine production quality management standards and to improve production efficiency due to aging equipment [4][6]. Group 4: Compliance and Policy Alignment - The investment aligns with national industrial policies promoting the development of the biopharmaceutical industry, particularly in the vaccine sector, which is considered a strategic emerging industry [12][14]. - The project is supported by government policies encouraging equipment upgrades in the pharmaceutical industry, aiming to enhance production quality and efficiency [6][7][14]. Group 5: Economic Benefits and Innovation - While the project does not directly generate financial benefits, it is expected to ensure the stable production of core products, thereby supporting ongoing R&D investments [12][15]. - The implementation of the project will enhance the company's technological innovation capabilities, allowing for better product performance and quality, which is essential for meeting increasing market demands [14][15].

Core Viewpoint - Chengdu Olin Biological Technology Co., Ltd. plans to issue RMB ordinary shares (A shares) to specific investors to raise a total of RMB 125.2929 million for the technical transformation project of its vaccine research and production base, enhancing its capital strength and profitability [1][2][6]. Group 1: Background and Purpose of the Issuance - The global pharmaceutical market is experiencing growth, with 2023 drug spending estimated at approximately USD 1.6 trillion, and expected to reach about USD 2.2 trillion by 2028, driven by increased drug usage and new product launches [2]. - In China, the pharmaceutical manufacturing industry achieved revenue of RMB 252.057 billion in 2023, with a projected market size of RMB 299.11 billion by 2030, reflecting a compound annual growth rate of 9.6% from 2020 to 2025 [3][4]. - The vaccine industry is a strategic focus for China's biopharmaceutical sector, supported by various government policies aimed at promoting high-quality development in disease prevention and control [5][6]. Group 2: Use of Proceeds - The funds raised will be used for the technical transformation of production lines that are currently outdated, aiming to improve production efficiency and reduce operational costs through automation and smart manufacturing upgrades [6][7]. - The company has established a dual-driven product development strategy focusing on upgrading traditional vaccines and developing innovative vaccines, particularly targeting "super bacteria" and adult vaccines [7][8]. Group 3: Financial Impact and Measures - The issuance is expected to enhance the company's production capacity and financial strength, optimizing its capital structure and reducing financial risks, thereby improving long-term profitability [6][8]. - The company has committed to measures to mitigate the dilution of immediate returns for existing shareholders, including ongoing product development and market expansion efforts [21][24]. Group 4: Compliance and Fairness of the Issuance - The issuance process has been authorized by the company's annual general meetings and complies with relevant legal regulations, ensuring fairness and protecting the interests of all shareholders [16][17]. - The selection of specific investors for the issuance adheres to regulatory requirements, ensuring that the chosen investors possess adequate risk recognition and financial capability [10][11].

成都欧林生物科技股份有限公司（以下简称"公司"）于 2024 年 10 月 29 日召开第六届董事会第十七次会议审议通过了《关于公司以简易程序向特定对象 发行股票预案的议案》等相关议案，于 2025 年 6 月 25 日召开第六届董事会第二 十一次会议通过了《关于公司以简易程序向特定对象发行股票竞价结果的议案》 关于以简易程序向特定对象发行人民币普通股 （A 股）股票预案修订说明的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688319 证券简称：欧林生物 公告编号：2025-037 成都欧林生物科技股份有限公司 《关于公司与特定对象签署附生效条件的股份认购协议的议案》等相关议案。 简易程序向特定对象发行 A 股股票预案（二次修订稿）的议案》《关于与特定 对象重新签署附生效条件的股份认购协议的议案》等相关议案。 导致公司控制权发生 4、更新了本次发行已履行决策程序的情况 变化 八、本次向特定对 根据公司董事会审议通过的向特定对象发行股票预案，本次发行募集资金总 额为 12,529.29 万元，符合以简易 ...

证券简称：欧林生物 证券代码：688319 成都欧林生物科技股份有限公司 以简易程序向特定对象发行人民币普通股 （A股）股票预案（二次修订稿） 本部分所述词语或简称与本预案"释义"所述词语或简称具有相同含义。 一、本次以简易程序向特定对象发行 A 股相关事项已获得公司 2023 年年度 股东大会、2024 年年度股东大会授权，经公司第六届董事会第十七次会议、第 六届董事会第二十一次会议及第七届董事会第二次会议审议通过，尚需上海证 券交易所审核通过并经中国证监会作出同意注册决定后方可实施。 二〇二五年八月 公司声明 1、本公司及董事会全体成员保证本预案内容真实、准确、完整，并确认不 存在虚假记载、误导性陈述或重大遗漏，对本预案内容的真实性、准确性、完 整 性承担个别和连带的法律责任。 2、本预案按照《上市公司证券发行注册管理办法》等要求编制。 3、本次以简易程序向特定对象发行股票完成后，公司经营与收益的变化由 公司自行负责；因本次以简易程序向特定对象发行股票引致的投资风险，由投 资 者自行负责。 4、本预案是公司董事会对本次以简易程序向特定对象发行股票的说明，任 何与之相反的声明均属不实陈述。 5、投资者如有任 ...

成都欧林生物科技股份有限公司关于以简易程序向特定对 象发行人民币普通股（A 股）股票预案（二次修订稿） 披露的提示性公告 证券代码：688319 证券简称：欧林生物 公告编号：2025-036 根据公司 2023 年年度股东大会及 2024 年年度股东大会的授权，本次修订预 案无需另行提交公司股东大会审议。 《成都欧林生物科技股份有限公司以简易程序向特定对象发行人民币普通 股（A 股）股票预案（二次修订稿）》等相关文件及公告已在上海证券交易所网 站（www.sse.com.cn）披露，敬请广大投资者注意查阅。 本次以简易程序向特定对象发行股票的预案披露不代表审核、注册部门对于 本次发行股票相关事项的实质性判断、确认或批准，预案所述本次发行相关事项 的生效和完成尚需上海证券交易所审核通过，并经中国证券监督管理委员会同意 注册。敬请广大投资者注意投资风险。 特此公告。 成都欧林生物科技股份有限公司董事会 2025 年 8 月 19 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 成都欧林生物科技股份有限公司（以下简称"公司 ...